Josephine Johnston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Josephine Johnston has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Erik Parens
The Hastings Center
5 shared publications - Annelien L. Bredenoord
Erasmus School of Philosophy, Erasmus University Rotterdam, Rotterdam, The Netherlands
2 shared publications - Françoise Baylis
Dalhousie University, Halifax, Nova Scotia, Canada
2 shared publications - Karin Rolanda Jongsma
University Medical Center Utrecht
2 shared publications - Michael Kelley Gusmano
Lehigh University
2 shared publications - Nienke de Graeff
Leiden University Medical Center
2 shared publications
Latest Publications
- Open Access
- 4 July 2026
- Published by Taylor & Francis in Bulletin of the Atomic Scientists
- Vol. 82 (4) , 279-283
Treat me like a human: The prescience of Children of Men
- 4 July 2026
- Published by Taylor & Francis in Bulletin of the Atomic Scientists
- Vol. 82 (4) , 279-283
Open AccessTreat me like a human: The prescience of Children of Men
- 18 September 2025
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 25 (10) , 37-40
Structural Features of Genetic Risk and the Need for a Relational Approach to Disclosure
- 18 September 2025
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 25 (10) , 37-40
Structural Features of Genetic Risk and the Need for a Relational Approach to Disclosure
- Open Access
- 3 July 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 65 (4) , 505-526
Systematic Review: The Psychosocial Impacts of Autism-Related Genetic Testing
- 3 July 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 65 (4) , 505-526
Open AccessSystematic Review: The Psychosocial Impacts of Autism-Related Genetic Testing
- 26 June 2024
- Published by BMJ in Journal of Medical Ethics
- Vol. 51 (5)
Understanding individualised genetic interventions as research-treatment hybrids
Until recently, medicine has had little to offer most of the millions of patients suffering from rare and ultrarare genetic conditions. But the development in 2019 of Milasen, the first genetic intervention developed for and administered to a single patient suffering from an ultrarare genetic disorder, has offered hope to patients and families. In addition, Milasen raised a series of conceptual and ethical questions about how individualised genetic interventions should be developed, assessed for safety and efficacy and financially supported. The answers to these questions depend in large part on whether individualised therapies are understood as human subjects research or clinical innovation, different domains of biomedicine that are regulated by different modes of oversight, funding and professional norms. In this article, with development and administration of the drug Milasen as our case study, we argue that at least some individualised genetic therapies are not, as some have argued, either research or treatment. Instead, they are research-treatment hybrids, a category that has both epistemological and pragmatic repercussions for funding, ethics oversight and regulation.
- 26 June 2024
- Published by BMJ in Journal of Medical Ethics
- Vol. 51 (5)
Understanding individualised genetic interventions as research-treatment hybrids
Until recently, medicine has had little to offer most of the millions of patients suffering from rare and ultrarare genetic conditions. But the development in 2019 of Milasen, the first genetic intervention developed for and administered to a single patient suffering from an ultrarare genetic disorder, has offered hope to patients and families. In addition, Milasen raised a series of conceptual and ethical questions about how individualised genetic interventions should be developed, assessed for safety and efficacy and financially supported. The answers to these questions depend in large part on whether individualised therapies are understood as human subjects research or clinical innovation, different domains of biomedicine that are regulated by different modes of oversight, funding and professional norms. In this article, with development and administration of the drug Milasen as our case study, we argue that at least some individualised genetic therapies are not, as some have argued, either research or treatment. Instead, they are research-treatment hybrids, a category that has both epistemological and pragmatic repercussions for funding, ethics oversight and regulation.
- Open Access
- 7 August 2023
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 378 (1886) , 20230202
Correction to: ‘The ethics of genome editing in non-human animals: a systematic review of reasons reported in the academic literature’ (2019) by de Graeff et al.
- 7 August 2023
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 378 (1886) , 20230202
Open AccessCorrection to: ‘The ethics of genome editing in non-human animals: a systematic review of reasons reported in the academic literature’ (2019) by de Graeff et al.
- 20 June 2023
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 23 (7) , 118-120
When Less is More: Lessons for Expanded Carrier Screening from Newborn Sequencing Research
- 20 June 2023
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 23 (7) , 118-120
When Less is More: Lessons for Expanded Carrier Screening from Newborn Sequencing Research
- 21 March 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (3) , 446-448
Polygenic embryo testing: understated ethics, unclear utility
New technologies are expanding the reach and accessibility of preimplantation genetic testing of human embryos. But what these advances can deliver is still unclear, and a frank assessment of their profound ethical implications is urgently needed.
- 21 March 2022
- Published by Springer Nature in Nature Medicine
- Vol. 28 (3) , 446-448
Polygenic embryo testing: understated ethics, unclear utility
New technologies are expanding the reach and accessibility of preimplantation genetic testing of human embryos. But what these advances can deliver is still unclear, and a frank assessment of their profound ethical implications is urgently needed.
- 22 June 2021
- Published by Springer Nature in Nature
- Vol. 594 (7864) , 495
ISSCR: grave omission of age limit for embryo research
- 22 June 2021
- Published by Springer Nature in Nature
- Vol. 594 (7864) , 495
ISSCR: grave omission of age limit for embryo research
- 1 March 2020
- Published by Wiley in Hastings Center Report
- Vol. 50 (2) , 4-5
Budgets versus Bans: How U.S. Law Restricts Germline Gene Editing
In late 2019, He Jiankui, the Chinese scientist who created the world's first gene‐edited babies, and two embryologists were sentenced to prison and fined. Thirteen months earlier, when the world first learned about the experiment, He and his colleagues drew swift and nearly uniform international condemnation for prematurely moving to human trials, for the risks they took with the children's health, and for He's secrecy. The organizing committee for the second genome editing summit said the experiment failed to conform with international norms.” In the United States, the legal picture is complex. No doubt the specific experiment He performed would have run afoul of long‐standing research regulations due to its problems with informed consent and ethical review. But other laws also affect this kind of work, in particular, a budget rider that for the past four years has been included in federal appropriations legislation.
- 1 March 2020
- Published by Wiley in Hastings Center Report
- Vol. 50 (2) , 4-5
Budgets versus Bans: How U.S. Law Restricts Germline Gene Editing
In late 2019, He Jiankui, the Chinese scientist who created the world's first gene‐edited babies, and two embryologists were sentenced to prison and fined. Thirteen months earlier, when the world first learned about the experiment, He and his colleagues drew swift and nearly uniform international condemnation for prematurely moving to human trials, for the risks they took with the children's health, and for He's secrecy. The organizing committee for the second genome editing summit said the experiment failed to conform with international norms.” In the United States, the legal picture is complex. No doubt the specific experiment He performed would have run afoul of long‐standing research regulations due to its problems with informed consent and ethical review. But other laws also affect this kind of work, in particular, a budget rider that for the past four years has been included in federal appropriations legislation.
- 1 January 2020
- Published by Project MUSE in Perspectives in Biology and Medicine
- Vol. 63 (1) , 141-154
Shaping the CRISPR Gene-Editing Debate: Questions About Enhancement and Germline Modification
Today's debate about the use of gene-editing technologies to alter human DNA brings together two longstanding lines of inquiry in bioethics: the ethics of human enhancement, and the ethics of heritable genetic modification. This article traces that lineage by identifying key distinctions and ethics questions in these preexisting lines of inquiry that are also employed in four recent policy and ethics statements on human gene editing. These distinctions and ethics questions can be helpful heuristics for organizing discussion, learning from existing analysis, and highlighting what is at stake with new gene-editing technologies. Yet scientists, policymakers, and others new to the ethics of emerging technologies should also be aware of both the limitations of these distinctions and past challenges in adequately addressing the ethics questions they raise. In particular, the treatment-enhancement distinction and the somatic-germline distinction are not as clear-cut as they might initially appear. More importantly, they cannot be used to definitively differentiate right from wrong uses of the technologies in question.
- 1 January 2020
- Published by Project MUSE in Perspectives in Biology and Medicine
- Vol. 63 (1) , 141-154
Shaping the CRISPR Gene-Editing Debate: Questions About Enhancement and Germline Modification
Today's debate about the use of gene-editing technologies to alter human DNA brings together two longstanding lines of inquiry in bioethics: the ethics of human enhancement, and the ethics of heritable genetic modification. This article traces that lineage by identifying key distinctions and ethics questions in these preexisting lines of inquiry that are also employed in four recent policy and ethics statements on human gene editing. These distinctions and ethics questions can be helpful heuristics for organizing discussion, learning from existing analysis, and highlighting what is at stake with new gene-editing technologies. Yet scientists, policymakers, and others new to the ethics of emerging technologies should also be aware of both the limitations of these distinctions and past challenges in adequately addressing the ethics questions they raise. In particular, the treatment-enhancement distinction and the somatic-germline distinction are not as clear-cut as they might initially appear. More importantly, they cannot be used to definitively differentiate right from wrong uses of the technologies in question.